Background: Most patients including health care workers (HCWs) survived the coronavirus disease 2019 (COVID-19), however, knowledge about the sequelae of COVID-19 after discharge remains limited. Methods: A prospectively observational 3-month follow-up study evaluated symptoms, dynamic changes of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) IgG and IgM, lung function, and high resolution computed tomography (HRCT) of survivors of COVID-19 after discharge at Wuhan Union Hospital, China. Results: Seventy-six survivors (55 females) with a mean age of 41.3 ± 13.8 years were enrolled, and 65 (86%) were HCWs. A total of 69 (91%) patients had returned to their original work at 3-months after discharge. Most of the survivors had symptoms including fever, sputum production, fatigue, diarrhea, dyspnea, cough, chest tightness on exertion and palpitations in the three months after discharge. The serum troponin-I levels during the acute illness showed high correlation with the symptom of fatigue after hospital discharge (r = 0.782; P = 0.008) and lymphopenia was correlated with the symptoms of chest tightness and palpitations on exertion of patients after hospital discharge (r = −0.285, P = 0.027; r = −0.363, P = 0.004, respectively). The mean values of forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC, total lung capacity and diffusion capacity were all normal (> 80% predicted) and lung HRCTs returned to normal in most of the patients (82%), however, 42% of survivors had mild pulmonary function abnormalities at 3-months after discharge. SARS-CoV-2 IgG turned negative in 11% (6 of 57 patients), 8% (4 of 52 patients) and 13% (7 of 55 patients), and SARS-CoV-2 IgM turned negative in 72% (41 of 57 patients), 85% (44 of 52 patients) and 87% (48 of 55 patients) at 1-month, 2-months and 3-months after discharge, respectively. Conclusion: Infection by SARS-CoV-2 caused some mild impairments of survivors within the first three months of their discharge and the duration of SARS-CoV-2 antibody was limited, which indicates the necessity of long-term follow-up of survivors of COVID-19.
BackgroundThe novel coronavirus (SARS-CoV-2) infected over 3,300 health-care-workers (HCWs) in early 2020 in China. Little information is known about nosocomial infections of HCWs in the initial period. We analyzed data from HCWs with nosocomial infections in Wuhan Union Hospital and their family members. MethodsWe collected and analyzed data on exposure history, illness timelines, and epidemiologic characteristics of 25 laboratory-confirmed and two highly suspected HCWs as well as ten of their family members with COVID-19 from Jan 5 to Feb 12, 2020. Among them, demographics and clinical features of the 35 laboratory-confirmed cases were investigated and viral RNA of 12 cases was sequenced and analyzed. ResultsNine clusters were found among the patients. All patients showed mild to moderate clinical manifestation and recovered without deterioration. The average periods of incubation, clinical onset serial interval (COSI), and virus shedding were 4.5 days, 5.2 ± 3.2 days, and 18.5 days, respectively. Complete genomic sequences of 12 different coronavirus strains demonstrated that the viral structure with small, irrelevant mutations was stable in the transmission chains and showed remarkable traits of infectious traceability. ConclusionsSARS-CoV-2 can be rapidly transmitted person-to-person regardless of whether they have symptoms in both hospital settings and social activities based on the short period of incubation and COSI. The public health service should take practical measures to curb the spread, including isolation of cases, tracing close-contacts, and containment of severe epidemic areas. Besides, the HCWs should be alert during the epidemic, and make self-quarantine if self-suspected. Nosocomial Outbreak of 2019 Novel
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.